Ao Biome Therapeutics
Biotechnology, 125 Cambridgepark Dr, Cambridge, Massachusetts, 02140, United States, 1-10 Employees
Phone Number: 61********
Who is AOBIOME THERAPEUTICS
AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic infla...
Read More
-
Headquarters: 125 Cambridgepark Dr, Cambridge, Massachusetts, 02140, United States
-
Date Founded: 2013
-
Employees: 1-10
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8711
|
NAICS Code: 541330 |
Show More
Does something look wrong? Fix it. | View contact records from AOBIOME THERAPEUTICS
AOBiome Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding AOBiome Therapeutics
Answer: AOBiome Therapeutics's headquarters are located at 125 Cambridgepark Dr, Cambridge, Massachusetts, 02140, United States
Answer: AOBiome Therapeutics's phone number is 61********
Answer: AOBiome Therapeutics's official website is https://aobiome.com
Answer: AOBiome Therapeutics's revenue is $10 Million to $25 Million
Answer: AOBiome Therapeutics's SIC: 8711
Answer: AOBiome Therapeutics's NAICS: 541330
Answer: AOBiome Therapeutics has 1-10 employees
Answer: AOBiome Therapeutics is in Biotechnology
Answer: AOBiome Therapeutics contact info: Phone number: 61******** Website: https://aobiome.com
Answer: AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month